Ipilimumab: controversies in its development, utility and autoimmune adverse events

@article{Weber2008IpilimumabCI,
  title={Ipilimumab: controversies in its development, utility and autoimmune adverse events},
  author={Jeffrey L. Weber},
  journal={Cancer Immunology, Immunotherapy},
  year={2008},
  volume={58},
  pages={823-830}
}
A promising new class of anti-cancer drugs includes antibodies that mediate immune regulatory effects. It has become very clear over the last decade that different types of immune cells and different pathways serve to suppress anti-cancer immunity, particularly in the microenvironment of the tumor. The first examples of immune modulating antibodies are those directed against cytotoxic T lymphocyte antigen-4 (CTLA-4), a molecule present on activated T cells. Human antibodies that abrogate the… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 119 CITATIONS

FILTER CITATIONS BY YEAR

2009
2018

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 7 Citations per year over the last 3 years

  • 9% Increase in citations per year in 2018 over 2017

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

Similar Papers

Loading similar papers…